GLOW 70mg
Results reported for the submitted sample
GLOW 70mg
- Lot in our record
- BBG-20260811-01
- Certificate ID
- COA7917
- Lot printed on the certificate
- BBG-20260811-01
Bioviridian Inc. · COA7917
- Reported identity
- GHK-Cu, BPC-157, TB-500
- LC-MS/MS
- Measured content / assay
- 50.43, 10.72, 10.26 mg
- HPLC Quantitation
- The document lists named components and multiple content values, but does not explicitly label each value with a component. Their comma order does not establish a mapping. Values remain unassigned.
- Chromatographic purity
- 99.84%
- RP-HPLC (214 nm)
- The single Overall Purity value applies only as reported for the blend. Individual component purities are not reported.
Testing scope
Results are reported for the submitted sample. They do not establish the identity or composition of every vial carrying a lot label.
We have not commissioned sterility or endotoxin testing for this material. This is the owner's statement about Purely Peptides' commissioning, not a claim about testing by upstream parties.
This report does not include a residual-solvent result.
These results do not establish suitability for human or veterinary use.
Independent issuer confirmation has not been recorded for this assessment. A hosted PDF or report code does not establish authenticity or physical-sample linkage.
Issuer and report details
Bioviridian Inc. is named on the certificate as the issuing laboratory. Independent issuer confirmation has not been recorded for this assessment (not checked).
Check the report with the issuing laboratoryUse certificate ID COA7917. Issuer confirmation would not by itself establish all-vial or physical-sample linkage.
Methods, reporting context and disclosure provenance
- Sample type
- Blue lyophilized powder
- Molecular weight (g/mol), as recorded
- 403.2, 1419.5, 4964.2
- Sample received
- 2026-08-18
- Report issued
- 2026-08-23
- HPLC retention time, as recorded
- 1.933, 9.112, 9.188 min
Results and methods retain the report record's original units and precision. A result here is not a finding that an acceptance specification was met.
Source: page 1, Test Results, Sample Information and Analytical Methods. Document annotations were visually inspected on 2026-09-18; no new laboratory authentication has been performed.
Commissioning disclosure: Purely Peptides owner's statement in the editorial and batch-results brief, bound to this inspected report and material. It is separate from document-derived absence of a residual-solvent result.
Published by Purely Peptides, a commercial research-material supplier. These documentation pages do not establish suitability for human or veterinary use.